Skip to main content
Fig. 1 | Allergy, Asthma & Clinical Immunology

Fig. 1

From: Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial

Fig. 1

a Mean ACQ-5 scores, b geometric mean blood eosinophil counts including proportions of subjects with mean ACQ-5 score ≥ 1.5/< 1.5 and blood eosinophil counts ≥ 150/< 150 cells/µL. Mean ACQ-5 scores and geometric blood eosinophil counts were measured during the open label period and following treatment discontinuation. Error bars represent 95% confidence interval. Reference line for a at a mean ACQ-5 score of 1.5. Reference line for b at a geometric mean blood eosinophil count of 150 cells/µL. ACQ-5 Asthma Control Questionnaire-5, SC subcutaneous

Back to article page